Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
San Antonio Breast Cancer Symposium (SABCS)
SABCS 2023 HER2+ mBC
SABCS 2023 HER2+ MBC
Trial in Progress: BRIDGET Trial of Tucatinib Plus Trastuzumab/Pertuzumab or Trastuzumab Emtansine After Isolated Intracranial Progression in HER2+ MBC
SABCS 2023 HER2+ MBC
The ongoing BRIDGET (NCT05323955) trial is a single-arm, phase 2, multicenter study that is evaluating the addition of tucatinib to trastuzumab/pertuzumab or trastuzumab emtansine after local therapy in patients with HER2+ metastatic breast cancer (MBC) with isolated brain relapse or progression.
Read More ›
Interstitial Lung Disease Incidence with Sequential Antibody–Drug Conjugate Use in MBC
SABCS 2023 HER2+ MBC
Findings of a small multi-institution retrospective study do not indicate a clear increased risk for interstitial lung disease with sequential treatment of antibody–drug conjugates in patients with metastatic breast cancer (MBC).
Read More ›
Real-World Evidence of the Effect of Body Mass Index on Treatment Outcomes in MBC
SABCS 2023 HER2+ MBC
Findings of a retrospective single-institution study indicates that higher body mass index (BMI) was associated with better survival outcomes compared with lower BMI in patients with metastatic/recurrent breast cancer.
Read More ›
Trial in Progress: Real-World Experience of Trastuzumab Deruxtecan in HER2+ and HER2-low Unresectable and/or MBC (DESTINY-Breast-RESPOND Trial)
SABCS 2023 HER2+ MBC
The DESTINY-Breast-RESPOND trial is a multicenter, prospective, observational study of trastuzumab deruxtecan that is evaluating the effectiveness and tolerability of trastuzumab deruxtecan in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (MBC) in a real-world setting.
Read More ›
Tolerability of Pertuzumab in Older Patients with HER2+ Breast Cancer
SABCS 2023 HER2+ MBC
Real-world evidence from a single-center experience showed that pertuzumab was well tolerated in older patients with HER2+ breast cancer in the real-world setting; however, a quarter of patients discontinued treatment due to toxicities.
Read More ›
Page 2 of 2
1
2
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us